A. Legrand

Effects of a slow‐release formulation of the new somatostatin analogue lanreotide in TSH‐secreting pituitary adenomas

A Gancel, P. Vuillermel, A. Legrand et al. · Clinical Endocrinology · 1994 · 84 citations

Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies.

Hervé Lefèbvre, Vincent Contesse, Catherine Delarue et al. · The Journal of Clinical Endocrinology & Metabolism · 1993 · 78 citations

Molecular Pharmacology, Adrenal Gland, Aldosterone Secretion +15

Cerebrotendinous xanthornatosis

Jacqueline Peynet, Annie Laurent, P. De Liege et al. · Neurology · 1991 · 51 citations

Severe Neurologic Form, Medicine, Pathology +3

The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man.

Hervé Lefèbvre, Vincent Contesse, Catherine Delarue et al. · The Journal of Clinical Endocrinology & Metabolism · 1995 · 43 citations

Molecular Pharmacology, Adrenal Gland, Aldosterone Secretion +12

Pharmacokinetic and pharmacodynamic properties of a long‐acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

J-M Kuhn, A. Legrand, J M Ruiz et al. · British Journal of Clinical Pharmacology · 1994 · 42 citations · Full text